ReviewActa Cardiologica Sinica2017
The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension.
Review in Acta Cardiologica Sinica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Systematic Review of Self-Measured Blood Pressure Monitoring With Support: Intervention Effectiveness and Cost.American journal of preventive medicine · 2022Pooled it
- Do we AGREE on the targets of antihypertensive drug treatment in older adults: a systematic review of guidelines on primary prevention of cardiovascular diseases.Age and ageing · 2022Pooled it
- The implications of blood pressure targets from the 2018 European Society of Cardiology hypertension guidelines in Asian patients: a systematic review and meta-analysis.Annals of Saudi medicinePooled it
- Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial.Journal of the Chinese Medical Association : JCMA · 2020Trial
- Target blood pressure and control status in Asia.Journal of clinical hypertension (Greenwich, Conn.) · 2020Trial
- Optimizing blood pressure control in multimorbid hypertensive patients: insights from a real-world taiwanese cohort.Journal of hypertension · 2026Article
- Effects of cancer on stroke recurrence and mortality: A single-center retrospective cohort study.eNeurologicalSci · 2023Article
- The 2023 Taiwan Stroke Society Guidelines for the management of patients with intracranial atherosclerotic disease.Journal of the Chinese Medical Association : JCMA · 2023Article
- 2021 Taiwan Stroke Society Guidelines of blood pressure control for ischemic stroke prevention.Journal of the Chinese Medical Association : JCMA · 2022Article
- 2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.Acta Cardiologica Sinica · 2022Article
- STEP Towards Better Blood Pressure Control: The Prime Time for a Universal Target of < 130/80 mmHg.Acta Cardiologica Sinica · 2021Article
- 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes.JACC. Asia · 2021Review
- Optimal blood pressure for patients with end-stage renal disease following coronary interventions.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Variation in hypertension clinical practice guidelines: a global comparison.BMC medicine · 2021Article
- Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial.Acta Cardiologica Sinica · 2021Article
- Long-Term Effect of Device-Guided Slow Breathing on Blood Pressure Regulation and Chronic Inflammation in Patients with Essential Hypertension Using a Wearable ECG Device.Acta Cardiologica Sinica · 2021Article
- Isolated systolic hypertension in Asia.Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- Diverse Adiposity and Atrio-Ventricular Dysfunction across Obesity Phenotypes: Implication of Epicardial Fat Analysis.Diagnostics (Basel, Switzerland) · 2021Article
- Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions.Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- 2020 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Home Blood Pressure Monitoring for the Management of Arterial Hypertension.Acta Cardiologica Sinica · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension (HT) is the most important risk factor for cardiovascular diseases. Over the past 25 years, the number of individuals with hypertension and the estimated associated deaths has increased substantially. There have been great debates in the past few years on the blood pressure (BP) targets. The 2013 European Society of Hypertension and European Society of Cardiology HT guidelines suggested a unified systolic BP target of 140 mmHg for both high-risk and low-risk patients. The 2014 Joint National Committee report further raised the systolic BP targets to 150 mmHg for those aged ≥ 60 years, including patients with stroke or coronary heart disease, and raised the systolic BP target to 140 mmHg for diabetes. Instead, the 2015 Hypertension Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society suggested more aggressive BP targets of < 130/80 mmHg for patients with diabetes, coronary heart disease, chronic kidney disease with proteinuria, and atrial fibrillation patients on antithrombotic therapy. Based on the main findings from the Systolic Blood Pressure Intervention Trial (SPRINT) and several recent meta-analyses, the HT committee members of the Taiwan Society of Cardiology and the Taiwan Hypertension Society convened and finalized the revised BP targets for management of HT. We suggested a new systolic BP target to < 120 mmHg for patients with coronary heart disease, chronic kidney disease with an eGFR of 20-60 ml/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.